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Abstract
Objectives To report the burden of cardiovascular diseases
(CVD) in the Eastern Mediterranean Region (EMR) during
1990–2015.
Methods We used the 2015 Global Burden of Disease study
for estimates of mortality and disability-adjusted life years
(DALYs) of different CVD in 22 countries of EMR.
Results A total of 1.4 million CVD deaths (95% UI:
1.3–1.5) occurred in 2015 in the EMR, with the highest
number of deaths in Pakistan (465,116) and the lowest
number of deaths in Qatar (723). The age-standardized
DALY rate per 100,000 decreased from 10,080 in
1990 to 8606 in 2015 (14.6% decrease). Afghanistan had
the highest age-standardized DALY rate of CVD in both
1990 and 2015. Kuwait and Qatar had the lowest age-s-
tandardized DALY rates of CVD in 1990 and 2015,
respectively. High blood pressure, high total cholesterol,
and high body mass index were the leading risk factors for
CVD.
Conclusions The age-standardized DALY rates in the
EMR are considerably higher than the global average.
These findings call for a comprehensive approach to pre-
vent and control the burden of CVD in the region.
Keywords Cardiovascular disease  Burden of disease 
Eastern Mediterranean Region
Introduction
The Global Burden of Disease (GBD) study documented that
cardiovascular diseases (CVD) have been the leading cause of
global mortality since 1980 (Institute for Health Metrics and
Evaluation 2017; Mortality and Causes of Death 2016). CVD
accounted for nearly one-third of all deaths worldwide in
2015. Meanwhile, the principal components of CVD, namely
stroke and ischemic heart disease, accounted for 85.1% (95%
uncertainty interval (UI): 84.7–85.5) of all deaths in the CVD
category in 2015 (Mortality and Causes of Death 2016).
Although the age-standardized mortality rates of CVD
have fallen by 27.3% in the last 25 years, the absolute number
of deaths due to CVD increased globally by 42.4% between
1990 and 2015 (2017). Most CVD deaths occur in low- and
middle-income countries (Mensah et al. 2015). The decline in
age-standardized rates is mainly due to preventive interven-
tions and better access to quality treatment for acute cardio-
vascular conditions such as myocardial infarction and stroke
(Smith 2011). CVD also impose a high economic burden on
health systems and society. For instance, CVD personal
spending in the United States was estimated to be 231.1 billion
USD in 2013 and was the largest disease category of personal
health care spending (Dieleman et al. 2016).
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The Eastern Mediterranean Region (EMR) comprises 22
countries with a population of nearly 580 million people,
with a diverse range in per capita gross national product
(maximum 83,990 USD for Qatar, minimum 610 USD for
Afghanistan) (World Development Indicators database
2017). To the best of our knowledge, there is no compre-
hensive report on the burden and mortality of CVD in the
EMR.
This study aimed to report findings on cardiovascular
diseases between 1990 and 2015, from the Global Burden
of Diseases, Injuries and Risk Factors Study (GBD 2015)
in the 22 countries of the EMR. This would be help us
better understand the burden of CVD and interventions
needed to control these diseases.
Methods
GBD 2015 covers 195 countries, 21 regions, and seven
super-regions from 1990 to 2015 for 315 diseases and
injuries, 2619 unique sequelae, and 79 risk factors by age
and sex. Detailed descriptions of the general methodolog-
ical approach of GBD 2015 and specific methodology used
for CVD have been provided elsewhere (GBD 2015
DALYs and Collaborators 2016; GBD 2015 Disease and
Injury Prevalence Collaborators 2016; GBD 2015 Mortal-
ity and Causes of Death Collaborators 2016).
We evaluated the burden of CVD in the Eastern
Mediterranean Region (EMR), which contains 22 coun-
tries: Afghanistan, Bahrain, Djibouti, Egypt, Iran, Iraq,
Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Pak-
istan, Palestine, Qatar, Saudi Arabia, Somalia, Sudan,
Syria, Tunisia, the United Arab Emirates (UAE), and
Yemen.
The category of CVD includes the ten most common
global causes of CVD-related death: rheumatic heart dis-
ease, ischemic heart disease, cerebrovascular disease (is-
chemic stroke and hemorrhagic stroke), hypertensive heart
disease, cardiomyopathy and myocarditis, atrial fibrillation
and flutter, aortic aneurysm, peripheral vascular disease,
endocarditis, and ‘‘other cardiovascular and circulatory
diseases.’’ Electronic supplementary table S1 shows the
International Classification of Diseases (ICD-10) codes for
each of the cardiovascular causes.
To estimate the number of deaths due to CVD, we
estimated all-cause mortality envelopes (total number of
deaths) for each country-year during 1990–2015; we used
all accessible data such as vital registration systems, sam-
ple registration data, and household recall of deaths. These
sources were used as inputs for cause of death models. We
used cause of death ensemble modeling (CODEm) to
estimate the number of deaths for each CVD by age, sex,
country, and year. The number of deaths for each cause and
life tables for all-cause mortality were used to calculate
years of life lost (YLLs) (GBD 2015 Morality and Causes
of Death Collaborators 2016; Roth et al. 2015a, b).
We updated our previous systematic reviews for the
GBD study separately for each of the non-fatal sequelae of
CVD. Data on epidemiologic measures (incidence, preva-
lence, and case fatality) were extracted from 170 data
sources. List of all sources (by cause and location) are
available at the Institute for Health Metrics and Evalua-
tion’s website (IHME 2016).
Bayesian meta-regression analysis through DisMod-MR
2.1 was used for disease modeling. Model-based preva-
lence estimates, in combination with disability weights,
were used to calculate cause-specific years lived with dis-
ability (YLDs) for each age, sex, location, and year. Dis-
ability-adjusted life years (DALYs) were calculated
through summation of YLLs and YLDs (DALYs and
Collaborators 2016; Disease et al. 2016).
We report 95% uncertainty intervals (UI) for each
estimate, including rates, numbers of deaths, and DALYs.
We estimated UIs by taking 1000 samples from the pos-
terior distribution of each quantity and using the 25th- and
975th-ordered draws of the uncertainty distribution.
Results
Mortality
The CVD death rate per 100,000 population in the EMR
decreased from 515.1 (95% UI: 491.7–541.5) in 1990 to
456.5 (95% UI: 431.5–484.2) in 2015 (Table 1). A total of
1,373,329 CVD deaths (95% UI: 1,290,959–1,465,047)
occurred in 2015 in the EMR, 54.8% of which were among
males. These deaths accounted for 34.1% (95% UI:
33.1–35.1) of all deaths in the region in 2015, compared to
30.2% (95% UI: 29.5–30.9) of all deaths in 1990. The
number of men dying from CVD was consistently higher
than the number of women during 1990–2015 (Fig. 1).
The total number of deaths from ischemic heart disease
(IHD) was 802,078 in 2015, which accounted for 58.4% of
the total number of deaths due to CVD in the EMR. There
were 637,640 additional deaths in 2015 compared to 1990,
out of which 62.5% was contributed by IHD.
Table 2 provides the total number of deaths and the age-
standardized death rates from CVD in 1990 and 2015 for
all EMR countries. In 2015, Afghanistan had the highest
age-standardized death rate from CVD, followed by Iraq
and Yemen. In most of the EMR countries, age-standard-
ized death rates for CVD decreased between 1990 and
2015, with the highest decreases in Bahrain, Qatar, Leba-
non, and Jordan.
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Electronic supplementary figure S1 shows the top-
ranked death rates for different CVD in EMR countries.
Ischemic heart disease was the leading cause of CVD
mortality in 20 countries of the EMR; the exceptions were
Djibouti and Somalia, where cerebrovascular disease (both
hemorrhagic and ischemic stroke) was the leading cause of
cardiovascular-related death.
YLLs
The age-standardized YLL rate decreased 15.3%, from
9618.7 (9148.6–10,141.7) per 100,000 in 1990–8145.0
(7628.6–8744.3) per 100,000 in 2015 (Electronic supple-
mentary table S2). In the region, Afghanistan had the
highest age-standardized YLL rate at 21,426.2
(17,105.2–26,544.7), followed by Yemen and Iraq (Elec-
tronic supplementary table S2). In all countries of the EMR
except Pakistan, age-standardized YLL rates decreased
from 1990 to 2015 (Electronic supplementary table S2).
YLDs
The years lived with disability caused by CVD in the EMR
increased from 1,058,839 (95% UI: 746,613–1409,913) in
1990 to 1,966,111 (95% UI: 1398,373–2597,819) in 2015.
The rate of YLD increased by 85.7% during 1990–2015 in
the EMR.
The age-standardized YLD rate in the EMR was 460.6
(329.2–603.6) per 100,000 in 2015, which showed very
little decrease compared to 1990 (461.1 per 100,000)
(Electronic supplementary table S2). Oman had the highest
age-standardized YLD rate in the region in both 1990 and
2015: it was 1261 (874.6–1722.1) per 100,000 in 2015,
which was about 2.7 times higher than the regional aver-
age. United Arab Emirates had the lowest age-standardized
YLD rate in the EMR, 296.8 per 100,000 in 1990 and 285.8
per 100,000 in 2015. Age-standardized YLD rates of CVD
decreased between 1990 and 2015 in six countries of the
region: Iran, United Arab Emirates, Jordan, Djibouti,
Somalia, and Afghanistan. The biggest decline was seen in
Iran (4.6%), and the smallest reduction was in Afghanistan
(0.5%). Among the remaining 16 countries of the region
that showed increases in age-standardized YLD rates of
CVD, Syria’s was the greatest, at 9.1%.
DALYs
The rate of DALYs from CVD per 100,000 population
decreased from 5447.8 (95% UI: 5168.2–5739.0) in
1990–5109.8 (95% UI: 4771.3–5511.1) in 2015, a 6.2%
decrease—compared to an 8.4% reduction in the DALY
rate for all other non-communicable diseases in the EMR.
The age-standardized DALY rate also decreased 14.6%
during 1990–2015 (Table 3). Table 3 reports numbers and
age-standardized rates of DALYs for different CVD in the
EMR in 1990 and 2015. The age-standardized DALY rate
of CVD for men and women in the EMR in 2015 was
higher than in other WHO regions. It was 1.51 times the
global rate for males and 1.86 times the global rate for
females. Electronic supplementary figure S2 shows the
age-standardized rates of DALYs for different CVD in men
and women. As shown, ischemic heart disease caused the
highest number of DALYs both in men (5771.9 per
100,000) and women (3931.2 per 100,000), followed by
hemorrhagic stroke and ischemic stroke.
Electronic supplementary figure S3 shows DALY rates
for each CVD in different age groups. As shown, the
highest DALY rates for IHD, hemorrhagic stroke, ischemic
stroke, and hypertensive heart disease were observed in
people aged 50–69 years. IHD, hemorrhagic stroke, and
rheumatic heart disease showed the highest number of
DALYs in the 15–49 years age group.
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Table 4 summarizes age-standardized DALY rates for
CVD in the EMR countries in 1990 and 2015. As shown,
DALY rates decreased in all EMR countries except Pak-
istan from 1990 to 2015; the greatest reductions in DALY
rates were seen in Bahrain (59.4%), Qatar (48.7%), and
Jordan (47%). Afghanistan had the highest age-standard-
ized CVD DALY rate in both 1990 and 2015. Kuwait had
the lowest age-standardized DALY rate of CVD in 1990,
and Qatar had the lowest in 2015.
Analyzing the components of DALYs, CVD had a
higher YLL rate compared to YLD rate: on average, YLLs
were 17.7 times higher than YLDs in the EMR. The YLL/
YLD ratio in the countries of the region showed a wide
range of variation, from 48.9 in Afghanistan to 3.7 in Oman
(Electronic supplementary table S2).
Risk factors
Figure 2 shows the contribution, in DALYs, of different
risk factors to different CVD. High blood pressure, high
total cholesterol, and high body mass index were the
leading risk factors for CVD, accounting for 17,159,331
DALYs, 9852,820 DALYs, and 8427,021 DALYs,
respectively.
The cluster of all dietary risk factors accounts for
19,803,725 DALYs, making it the leading risk factor for
CVD, higher than even high blood pressure. Low whole
grains, low fruit, low vegetables, and high sodium intake
were the most important dietary risk factors.
Discussion
This study shows that CVD are the leading cause of disease
burden in the EMR as a whole and in most of the countries
of the region. Close to 33 million years of life were lost due
to premature mortality or disability from CVD, and more
than 1.3 million people died in the EMR in 2015,
accounting for around one-third of all deaths in the region.
Previous studies have also reported CVD deaths as the
main cause of death, for instance, 45% in the West Bank
(Palestine), 45% in Aleppo (Syria), 35% in Jordan, and
25% in UAE (Barakat et al. 2012; Loney et al. 2013; Shara
2010). A study in Europe has reported CVD mortality as
making up half of all deaths (Nichols et al. 2014).
CVD age-standardized mortality was considerably
higher than the global average (456 compared to 286 per
100,000); however it shows a declining trend over the past
25 years in most of the EMR countries. Countries with
higher declines (Bahrain, Qatar, Lebanon, and Jordan)
were among the countries in the fourth Socio-demographic
Index quartile category. In another GBD study, we esti-
mated an index for healthcare access and quality which is a
composite index based on estimates of mortality amenable
Fig. 2 Number of disability-adjusted life years for different cardiovascular diseases attributed to different risk factors, Global Burden of Disease
study, Eastern Mediterranean Region, 2015
S144 GBD 2015 Eastern Mediterranean Region Cardiovascular Disease Collaborators
123
to personal health care and varies between 0 (worst) and
100 (best). The index showed substantial heterogeneity
with a range between 32 (Afghanistan) and 85 (Qatar) in
2015 in the EMR. Linking these results to the findings of
our study showed that the countries with lower age-stan-
dardized DALY rates due to CVD had a higher index for
healthcare access and quality, and vice versa. This restates
the importance of increasing access to and quality of health
care to reduce CVD burden (Barber et al. 2017).
In the EMR, YLLs are the main component of CVD
burden. A global-level assessment showed that for overall
CVD, YLL rates were lowest in both the lowest and highest
socio-demographic groups, with an increase for those in the
middle of the socio-demographic rankings. It has been
suggested that medical care in countries with the highest
Socio-demographic Index might have increased life
expectancy to the point where CVD is most prevalent,
while people in the lowest socio-demographic group are
dying from other competing conditions before reaching the
common age for developing ischemic heart disease and
stroke. Based on this hypothesis, people living in countries
in the middle range of the socio-demographic rankings are
surviving long enough to develop ischemic heart disease
but do not have access to optimal medical or surgical
treatment (GBD 2015 Mortality and Causes of Death
Collaborators 2016).
These findings call for a comprehensive approach to
prevent and control the burden of CVD in the region. This
approach should include a road map for better monitoring
of the burden in EMR countries, with a focus on potential
variations in risk and care by regions within the countries.
It should also include programs for increasing awareness
among the general population of the importance of con-
trolling CVD risk factors.
The United Nations has set targets to decrease mortality
from non-communicable diseases (Sustainable Develop-
ment Goals, target 3.4.1), and CVD is at the center of this
target (GBD 2015 SDGs Collaborators 2016). The World
Health Organization has suggested a package of essential
non-communicable disease interventions for primary health
care in low-resource settings (PEN). These interventions
include a mixture of cost-effective population-wide and
individual approaches to reduce the burden of major non-
communicable diseases, such as methods for early detec-
tion and diagnosis using inexpensive technologies, non-
pharmacological and pharmacological approaches for
modification of risk factors, and affordable medications for
prevention and treatment of heart attacks and strokes,
diabetes, cancer, and asthma (World-Health-Organization
2010).
Our study showed that increased blood pressure is the
most important risk factor for CVD in the EMR, followed
by high total cholesterol and high body mass index.
A Cochrane systematic review showed that multiple risk
factor interventions may lower systolic and diastolic blood
pressure, body mass index, and waist circumference in low-
and middle-income countries (Uthman et al. 2015).
Previous studies show a high percentage of undiagnosed
CVD risk factors, such as diabetes and hypertension, in the
region (Abd El-Aty et al. 2015; El Bcheraoui et al.
2014a, b; Najafipour et al. 2014). The evidence shows that
delayed detection and undiagnosed risk factors, especially
diabetes, are strong predictors of fatal CVDs (Nakagami
et al. 2006). Based on reports from the region, required
care and services (such as medications) are underutilized in
diagnosed cases, even in high-income countries like Saudi
Arabia (Moradi-Lakeh et al. 2016). Underutilization of
medications is a function of availability, accessibility,
affordability, acceptability, and quality of medicines (and
care), as well as adherence to medical recommendations
(Behnood-Rod et al. 2016; Najafipour et al. 2014; van
Mourik et al. 2010; Wirtz et al. 2016). The Prospective
Urban Rural Epidemiology (PURE) study showed great
variation in availability, affordability, and use of medica-
tions for CVD, between and within countries. Countries
with less control over production, importation, distribution
chains, and retail outlets are specifically at risk of sub-
standard quality and falsification of medicines (Khatib
et al. 2016). All these factors are important to achieve
desired health outcomes in the field of CVD. CVD pre-
vention and control programs should improve the per-
ceived need and demand of the population for early
detection and use of the prevention/control services. The
study on CVD mortality forecast in 2015 has shown that
the MENA region will not achieve the target of 25%
reduction of CVD mortality by 2025 without achieving all
major targets for risk factor reduction (i.e., reducing the
prevalence of elevated systolic blood pressure by 25%,
reducing the prevalence of smoking by 30%, halting the
rise in elevated body mass index, and halting the rise in
fasting plasma glucose). Moreover, reports of health sys-
tem challenges in controlling and managing CVD in some
of the EMR countries reemphasize the need for significant
investment and improvement of access (Roth et al.
2015a, b; Romdhane et al. 2015; Ahmad et al. 2015).
Our study has some limitations; accurate data on car-
diovascular events (especially non-fatal outcomes) are
limited in many countries, including the EMR countries.
We used the standard GBD methodology by using study-
and country-level covariates for adjustment and estimation
of epidemiologic measures. Our study does not account for
variation within countries.
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Conclusion
Most of the EMR countries have launched programs to
reduce the burden of non-communicable disease, but they
generally do not have widespread programs to combat
CVD. This study calls for strengthening efforts to design
and launch comprehensive programs to cover all aspects of
prevention and control of CVDs through evidence-in-
formed, efficient interventions. The countries should
establish or improve information systems such as surveil-
lance sy stems to provide valid and accurate information
for policymaking and monitoring of the situation.
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